Lexeo Therapeutics Common Stock Statistics
Share Statistics
Lexeo Therapeutics Common Stock has 33.07M shares outstanding. The number of shares has increased by 24.08% in one year.
| Shares Outstanding | 33.07M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 23.81M |
| Failed to Deliver (FTD) Shares | 8 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 2.19M, so 6.64% of the outstanding shares have been sold short.
| Short Interest | 2.19M |
| Short % of Shares Out | 6.64% |
| Short % of Float | 9.21% |
| Short Ratio (days to cover) | 6.55 |
Valuation Ratios
The PE ratio is -5.39 and the forward PE ratio is -2.78.
| PE Ratio | -5.39 |
| Forward PE | -2.78 |
| PS Ratio | 0 |
| Forward PS | 355.7 |
| PB Ratio | 3.15 |
| P/FCF Ratio | -5.99 |
| PEG Ratio | n/a |
Enterprise Valuation
Lexeo Therapeutics Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.21, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.21 |
| Quick Ratio | 7.21 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.24 |
| Cash Flow / Debt | -22.84 |
| Interest Coverage | -334.21 |
Financial Efficiency
Return on equity (ROE) is -0.58% and return on capital (ROIC) is -54.73%.
| Return on Equity (ROE) | -0.58% |
| Return on Assets (ROA) | -0.47% |
| Return on Capital (ROIC) | -54.73% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -962.23K |
| Employee Count | 69 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -44.68% in the last 52 weeks. The beta is 0, so Lexeo Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -44.68% |
| 50-Day Moving Average | 8.11 |
| 200-Day Moving Average | 12.06 |
| Relative Strength Index (RSI) | 43.1 |
| Average Volume (20 Days) | 440.04K |
Income Statement
In the last 12 months, Lexeo Therapeutics Common Stock had revenue of $0 and earned -$66.39M in profits. Earnings per share was $-2.49.
| Revenue | 0 |
| Gross Profit | -1.84M |
| Operating Income | -68.51M |
| Net Income | -66.39M |
| EBITDA | -66.67M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.49 |
Balance Sheet
The company has $121.47M in cash and $11.64M in debt, giving a net cash position of $109.83M.
| Cash & Cash Equivalents | 121.47M |
| Total Debt | 11.64M |
| Net Cash | 109.83M |
| Retained Earnings | -181.84M |
| Total Assets | 173.87M |
| Working Capital | 132.64M |
Cash Flow
In the last 12 months, operating cash flow was -$59.50M and capital expenditures -$165.00K, giving a free cash flow of -$59.66M.
| Operating Cash Flow | -59.50M |
| Capital Expenditures | -165.00K |
| Free Cash Flow | -59.66M |
| FCF Per Share | -2.24 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
LXEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.98% |
| FCF Yield | -26.09% |
Analyst Forecast
The average price target for LXEO is $24.5, which is 254% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.5 |
| Price Target Difference | 254% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.39 |
| Piotroski F-Score | 2 |